Article

A prospective investigation of serum 25-hydroxyvitamin D and risk of lymphoid cancers

Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI 96813, USA.
International Journal of Cancer (Impact Factor: 5.01). 02/2009; 124(4):979-86. DOI: 10.1002/ijc.23984
Source: PubMed

ABSTRACT Studies indicate that higher sun exposure, especially in the recent past, is associated with reduced risk of non-Hodgkin lymphoma (NHL). Ultraviolet radiation-derived vitamin D may be protective against lymphomagenesis. We examined the relationship between prediagnostic serum 25-hydroxyvitamin D (25(OH)D) and lymphoid cancer risk in a case-control study nested within the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study cohort (1985-2002) of 29,133 Finnish male smokers (ages 50-69). We identified 270 incident lymphoid cancer cases and matched them individually with 538 controls by birth-year and month of fasting blood draw at baseline. In conditional logistic regression models for 10 nmol/L increments or tertile comparisons, serum 25(OH)D was not associated with the risk of overall lymphoid cancers, NHL (n = 208) or multiple myeloma (n = 41). Odds ratios (OR) for NHL for higher tertiles were 0.75 (95% confidence interval (CI), 0.50, 1.14) and 0.82 (95% CI, 0.53, 1.26). The 25(OH)D-NHL association, however, differed by follow-up duration at diagnosis. Cases diagnosed less than 7 years from the baseline showed an inverse association (OR for highest vs. lowest tertile = 0.43; 95% CI: 0.23, 0.83; p for trend = 0.01), but not later diagnoses (OR = 1.52; 95% CI: 0.82, 2.80; p for trend = 0.17). The inverse association found for close exposure to diagnosis was not confounded by other risk factors for lymphoma or correlates of 25(OH)D. Although our findings suggest that circulating 25(OH)D is not likely associated with overall lymphoid cancer, they indicate a potentially protective effect on short-term risk of NHL.

Download full-text

Full-text

Available from: Ronald L Horst, Jul 06, 2015
0 Followers
 · 
142 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Increasingly, scientists are debating whether photochemical synthesis of vitamin D in Western countries is adequate, and whether dietary intakes can plug the gap between endogenous vitamin D production and requirements, particularly in young and older populations. The debate is driven by the plethora of evidence suggesting that, in addition to its important role in maintaining bone health, vitamin D may be involved in ameliorating cell ageing and preventing cardiovascular disease, diabetes, immune dysfunction and some cancers. Observational evidence from different populations suggests a significant degree of vitamin D insufficiency, often defined as plasma 25-hydroxyvitamin D [25(OH)D] <25 nmol/l. Some experts have argued that daily intakes up to 40 µg/day may be needed to ensure a desirable vitamin D status, even after accounting for sun exposure. However, there is presently no consensus on the most appropriate vitamin D status for maintaining bone health and preventing chronic disease. In addition, the UK has not set a vitamin D recommendation for most adults under 65 years. Given the plethora of information about vitamin D and bone health, this article reviews evidence for a link between vitamin D and other aspects of health. In conclusion, three actions are suggested: (1) agreement on optimal plasma 25(OH)D levels for health; (2) a debate on whether UK dietary recommendations need revision; and (3) better promotion of dietary vitamin D via food sources and, for certain groups, supplements.
    Nutrition Bulletin 05/2009; 34(2):185 - 197. DOI:10.1111/j.1467-3010.2009.01755.x
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Substantive evidence implicates vitamin D receptor (VDR) or its natural ligand 1alpha,25-(OH)2 D3 in modulation of tumor growth. However, both human and animal studies indicate tissue-specificity of effect. Epidemiological studies show both inverse and direct relationships between serum 25(OH)D levels and common solid cancers. VDR ablation affects carcinogen-induced tumorigenesis in a tissue-specific manner in model systems. Better understanding of the tissue-specificity of vitamin D-dependent molecular networks may provide insight into selective growth control by the seco-steroid, 1alpha,25-(OH)2 D3. This commentary considers complex factors that may influence the cell- or tissue-specificity of 1alpha,25-(OH)2 D3/VDR growth effects, including local synthesis, metabolism and transport of vitamin D and its metabolites, vitamin D receptor (VDR) expression and ligand-interactions, 1alpha,25-(OH)2 D3 genomic and non-genomic actions, Ca2+ flux, kinase activation, VDR interactions with activating and inhibitory vitamin D responsive elements (VDREs) within target gene promoters, VDR coregulator recruitment and differential effects on key downstream growth regulatory genes. We highlight some differences of VDR growth control relevant to colonic, esophageal, prostate, pancreatic and other cancers and assess the potential for development of selective prevention or treatment strategies.
    Biochemical pharmacology 10/2009; 79(1):1-9. DOI:10.1016/j.bcp.2009.09.005 · 4.65 Impact Factor